Dissociating the Clinical Role and Economic Value of Intranasal Esketamine

J Manag Care Spec Pharm. 2020 Jan;26(1):20-22. doi: 10.18553/jmcp.2020.26.1.20.

Abstract

No funding supported the writing of this commentary. The author has nothing to disclose.

MeSH terms

  • Administration, Intranasal
  • Aerosols
  • Affect / drug effects*
  • Antidepressive Agents / administration & dosage*
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / economics*
  • Cost-Benefit Analysis
  • Depressive Disorder, Treatment-Resistant / diagnosis
  • Depressive Disorder, Treatment-Resistant / drug therapy*
  • Depressive Disorder, Treatment-Resistant / economics*
  • Depressive Disorder, Treatment-Resistant / psychology
  • Drug Costs*
  • Evidence-Based Medicine
  • Humans
  • Ketamine / administration & dosage*
  • Ketamine / adverse effects
  • Ketamine / economics*
  • Patient Safety
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Aerosols
  • Antidepressive Agents
  • Esketamine
  • Ketamine